Clinical trial NCT02869438: A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
Official title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Keywords: Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2016-08-17
Enrollment: 233
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.


Eligibility criteria: Inclusion criteria

1. Written informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union (EU) guidelines.
2. Female and male aged 18 to 75 years inclusively at the time of Visit 1
3. Documented current treatment with ICS and LABA for at least 30 days prior to Visit 1. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. Additional asthma controller medications, eg, oral corticosteroids, long-acting antimuscarinics (LAMAs), LTRAs, theophylline etc. are allowed if they have been used for at least 30 days prior to Visit 1
4. History of at least 2 asthma exacerbations that required treatment with systemic corticosteroids (intramuscular (IM), intravenous (IV), or oral) in the 12 months prior to Visit 1. For patients receiving corticosteroids as a maintenance therapy, the corticosteroid treatment for the exacerbation is defined as a temporary increase of their maintenance dose.
5. Pre-bronchodilator (pre-BD) FEV1 of \< 80% predicted at Visit 2 or Visit 3
6. ACQ-6 score ≥1.5 at Visit 1
7. Evidence of asthma as documented by airway reversibility (FEV1 ≥12% and 200 ml) demonstrated at Visit 1, Visit 2 or Visit 3. For patients entering the body plethysmography sub-study, reversibility must be demonstrated at Visit 1 or at Visit 2 only
8. Peripheral blood eosinophil count of ≥300 cells/μL assessed by central lab at Visit 1
9. Women of childbearing potential (WOCBP) must use an effective form of birth control confirmed by the Investigator. WOCBP must also have negative serum pregnancy test result on Visit 1.

   Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following agespecific requirements apply:
   * Women \<50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
   * Women ≥50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
10. All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose
11. Weight of ≥40 kg

Additional inclusion criteria applicable for the Body Plethysmography substudy 1.Residual volume ≥125% of predicted at Visit 3.

Inclusion criteria at randomization visit

1. At least 1 of the following within 7 days prior to randomization:

   * Daytime or nighttime asthma symptoms for 2 or more days;
   * Rescue SABA use for 2 or more days;
   * Nighttime awakenings due to asthma at least 1 night during the 7-day period
2. ACQ \>0.75 at Visit 4 prior to randomization.
3. A negative urine pregnancy test in WOCBP prior to administration of IP

Exclusion criteria

1. Clinically important pulmonary disease other than asthma (eg, active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome)
2. Life-threatening asthma defined as episodes requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episodes within the 12 months prior to Visit 1.
3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
4. An upper respiratory tract infection or an asthma exacerbation that required treatment with systemic corticosteroids or an increase in regular maintenance dose of OCS during the screening/run-in period prior to randomization Visit 4
5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

   * Affect the safety of the patient throughout the study
   * Influence the findings of the studies or their interpretations
   * Impede the patient's ability to complete the entire duration of study
6. Known history of allergy or reaction to any component of the investigational product formulation
7. History of anaphylaxis to any biologic therapy
8. History of Guillain-Barré syndrome
9. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy
10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
11. Any clinically significant cardiac disease or any electrocardiogram (ECG) abnormality obtained during the screening/run-in period, which in the opinion of the Investigator may put the patient at risk or interfere with study assessments
12. History of alcohol or drug abuse within 12 months prior to the date informed consent is obtained
13. Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll
14. A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test
15. Current smokers or former smokers with a smoking history of ≥10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1
16. Current malignancy, or history of malignancy, except for:

    * Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained.
    * Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.
17. Use of immunosuppressive medication (including but not limited to: oral corticosteroids \[for reasons other than asthma\], methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroids or any experimental anti-inflammatory therapy) within 3 months prior to the date informed consent
18. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥1.5 times the upper limit of normal (ULN) confirmed during screening period
19. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained
20. Receipt of any marketed (eg, omalizumab, mepolizumab etc.) or investigational biologic within 4 months or 5 half-lives prior to the date informed consent is obtained, whichever is longer
21. Receipt of live attenuated vaccines 30 days prior to the date of randomization
22. Receipt of any investigational medication within 30 days or 5 half-lives prior to randomization, whichever is longer
23. Previously received benralizumab (MEDI-563)
24. Planned surgical procedures during the conduct of the study
25. Currently breastfeeding or lactating women
26. Previous randomization in the present study
27. Concurrent enrolment in another interventional or post-authorization safety study (PASS).
28. AstraZeneca staff involved in the planning and/or conduct of the study
29. Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals

Exclusion criteria at randomization Visit 4

1. Greater than/equal to 20% change in mean Pre BD FEV1 value at randomization Visit 4 from the mean pre BD FEV1 calculated from the pre BD FEV1 recorded at Visit 2 and Visit 3

Primary outcomes:
measure: Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1
timeFrame: From first IP dose to Day 84
measure: Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)
timeFrame: From first IP dose to Day 84
Secondary outcomes:
measure: Percent Change From Baseline to End of Treatment in Eosinophils Counts
timeFrame: From first IP dose to Day 84
measure: Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to Post Baseline for Pre-BD FVC
timeFrame: From first IP dose to Day 84
measure: Percentage of Pre-BD FEV1 Responder
timeFrame: From first IP dose to Day 84
measure: Change From Baseline in ACQ-6
timeFrame: From first IP dose to Day 84
measure: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ)
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in FeNO
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients
timeFrame: From first IP dose to Day 84
measure: Duration of IP Administration
timeFrame: From first IP to last IP
Other outcomes:
measure: Serum Concentration of Benralizumab
timeFrame: From first dose to end of treatment period (Day 84)
measure: PK Parameter of Benralizumab (Cmax)
timeFrame: First IP dose cycle (ie, data collected on Days 3, 7, 14 and 28)
measure: Anti-drug Antibody Responses
timeFrame: From first IP dose to end of treatment period (Day 84)
measure: Change From Baseline to End of Treatment in PGI-S
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in CGI-C
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in PGI-C
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in Specific Airway Resistance (SGaw) for Sub-study Patients
timeFrame: From first IP dose to Day 84
measure: Change From Baseline to End of Treatment in Airway Resistance (Raw) for Sub-study Patients
timeFrame: From first IP dose to Day 84
Locations:
city: Scottsboro
country: United States
facility: Research Site
state: Alabama
city: Gilbert
country: United States
facility: Research Site
state: Arizona
city: Denver
country: United States
facility: Research Site
state: Colorado
city: Miami
country: United States
facility: Research Site
state: Florida
city: Tampa
country: United States
facility: Research Site
state: Florida
city: Vero Beach
country: United States
facility: Research Site
state: Florida
city: Winter Park
country: United States
facility: Research Site
state: Florida
city: Fort Mitchell
country: United States
facility: Research Site
state: Kentucky
city: Rochester
country: United States
facility: Research Site
state: Minnesota
city: New Bern
country: United States
facility: Research Site
state: North Carolina
city: Cincinnati
country: United States
facility: Research Site
state: Ohio
city: Oklahoma City
country: United States
facility: Research Site
state: Oklahoma
city: Medford
country: United States
facility: Research Site
state: Oregon
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Lampasas
country: United States
facility: Research Site
state: Texas
city: McKinney
country: United States
facility: Research Site
state: Texas
city: Curico
country: Chile
facility: Research Site
city: Santiago
country: Chile
facility: Research Site
city: Santiago
country: Chile
facility: Research Site
city: Santiago
country: Chile
facility: Research Site
city: Bamberg
country: Germany
facility: Research Site
city: Darmstadt
country: Germany
facility: Research Site
city: Frankfurt am Main
country: Germany
facility: Research Site
city: Frankfurt am Main
country: Germany
facility: Research Site
city: Frankfurt
country: Germany
facility: Research Site
city: Hamburg
country: Germany
facility: Research Site
city: Hamburg
country: Germany
facility: Research Site
city: Hannover
country: Germany
facility: Research Site
city: Hannover
country: Germany
facility: Research Site
city: Hannover
country: Germany
facility: Research Site
city: Mainz
country: Germany
facility: Research Site
city: München
country: Germany
facility: Research Site
city: Balassagyarmat
country: Hungary
facility: Research Site
city: Edelény
country: Hungary
facility: Research Site
city: Farkasgyepü
country: Hungary
facility: Research Site
city: Gödöllő
country: Hungary
facility: Research Site
city: Hajdúnánás
country: Hungary
facility: Research Site
city: Komárom
country: Hungary
facility: Research Site
city: Miskolc
country: Hungary
facility: Research Site
city: Pécs
country: Hungary
facility: Research Site
city: Pécs
country: Hungary
facility: Research Site
city: Cheongju-si
country: Korea, Republic of
facility: Research Site
city: Daegu
country: Korea, Republic of
facility: Research Site
city: Jeonju-si
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Iloilo City
country: Philippines
facility: Research Site
city: Lipa City
country: Philippines
facility: Research Site
city: Manila
country: Philippines
facility: Research Site
city: Quezon City
country: Philippines
facility: Research Site
Study officials:
affiliation: Child Health Institute of NJ, 89 French Street, Suite 4210, New Brunswick, NJ, 08901, USA
name: Reynold A Panettieri, Doctor of Medicine
role: PRINCIPAL_INVESTIGATOR
References: